ANGELA AMENDOLA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant NEW YORK, NY NPI 1447267604
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant NY Novo Nordisk AS All categories
General Payments — all program years on this page
$5,126.27
- Category: General Payments
- Program years: PY2021–2024
- Record count: 87
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $597.87 across 9 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $597.87 | 9 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $157.78 | 3 |
| Xeris Pharmaceuticals, Inc. | $150.00 | 1 |
| Lilly USA, LLC | $140.80 | 3 |
| Abbott Laboratories | $119.02 | 1 |
| CeQur Corporation | $30.27 | 1 |
By program year
Records — PY2024 (9)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1099649591 | CeQur Corporation | $30.27 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1100376423 | Novo Nordisk Inc | $11.05 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1100387761 | Novo Nordisk Inc | $124.39 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1100470824 | Novo Nordisk Inc | $22.34 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1125069591 | Abbott Laboratories | $119.02 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1135448047 | Lilly USA, LLC | $6.47 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1135472907 | Lilly USA, LLC | $125.00 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1135502606 | Lilly USA, LLC | $9.33 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1144620227 | Xeris Pharmaceuticals, Inc. | $150.00 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.